Role of Convalescent Plasma Therapy in Patients with Moderate to Severe COVID 19

Author(s): Khurshid Ahmad Khan, Muhammad Kamran Rauf, Asma Afzal Khan, Javeid Iqbal, Sadia Taj, Fatima Shahid, Aijaz Zeeshan Khan Chachar

Significance: Given the lack of evidence of effective treatments and vaccines for Corona virus disease-19(COVID-19), several treatment options are under investigation, including Convalescent Plasma. The FDA granted emergency use authorization (EUA) on August 23, 2020 for use of convalescent plasma in hospitalized patients with COVID-19 but further data from randomized clinical trials are needed. Objective: The objective of the study was to find evidence of efficacy of Convalescent Plasma therapy in patients with moderate to severe COVID-19. Study Design, Setting, and Sample size: Open label, observational study, where participants were allocated using predefined assessment criteria. The study included 42 patients admitted in Fatima Memorial Hospital, Lahore with moderate to severe COVID-19. The study was terminated early after 42 patients of a planned sample size of 50 patients due to no further admissions of COVID-19 in the hospital. Groups: Standard treatment for COVID-19 disease (antibiotics, steroids, Tocilizumab, Remdesivir) according to disease severity was given in 15 patients (control group), while Convalescent plasma was administered in addition to standard treatment in 27 patients (cases). Primary and Secondary Outcomes: Primary outcome was to see clinical improvement in patients with moderate to severe COVID-19, defined as patient recovered and discharged home. Secondary outcomes looked at oxygen requirement in both cases and controls after administration of treatment and any improvement in biochemical markers. Results: 42 patients were observed in the study. 27 patients assigned to the cases group received standard treatment and convalescent plasma therapy for moderate to severe Covid-19 disease whilst 15 patients received standard treatment only, assigned as control group. The median age of patients in the convalescent plasma group was 59.81±10.14 and 54.37 ±12.93 in the control group (p-value = 0.086). There was no statistically significant difference in baseline characteristics between the cases and control group. Primary outcome measured as patient recovered and discharged home was achieved in 64.3% of patients in the cases group and 35.7% in the control group (p value = 1). Secondary outcome compared oxygen requirements in cases (median 20 l/min) and controls (median 8 l/min) after treatment. There was no statistically significant difference in oxygen requirements between cases and controls after treatment (p=0.059). Biochemical markers of inflammatory response such as Total leukocyte count, D-dimer, Lactate dehydrogenase (LDH) did not show any statistically significant difference in the two groups. CRP however decreased markedly in those patients treated with Convalescent plasma in addition to standard treatment when compared with control group (p value= 0.002). Also, serum Ferritin was also found to be much lower in cases as compared to controls (p value = 0.001). No adverse effects were seen in the cases after administration of convalescent plasma. Conclusion: Convalescent Plasma therapy administered in addition to standard treatment did not result in a statically significant improvement in patient survival in patients with moderate to severe COVID-19 when compared with standard treatment alone. There was however, a significant reduction in two inflammatory markers associated with severe disease i.e. C-reactive protein (CRP) and serum Ferritin in the cases group. The study results may have failed to detect a clinically significant difference because of early termination of the study resulting in small sample size.

Covid-19, SARS-CoV-2, Corona Virus, Convalescent Plasma Therapy

1. 1.G. Marano, S. Vaglio, S. Pupella, G. Facco, L. Catalano, G.M. Liumbruno, et al.Convalescent plasma: New evidence for an old therapeutic tool?
2. Blood Transfus, 14 (2016), pp. 152-157, 10.2450/2015.0131-15
3. T. Burnouf, J. SeghatchianEbola virus convalescent blood products: Where we are now and where we may need to go
4. TransfusApher Sci, 51 (2014), pp. 120-125, 10.1016/j.transci.2014.10.003
5. J. Mair-Jenkins, M. Saavedra-Campos, J.K. Baillie, P. Cleary, F.-M. Khaw, W.S. Lim, et al.The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis
6. J Infect Dis, 211 (2015), pp. 80-90, 10.1093/infdis/jiu396
7. M. Rojas, D.M. Monsalve, Y. Pacheco, Y. Acosta-Ampudia, C. Ramírez-Santana, A.A. Ansari, et al.Ebola virus disease: An emerging and re-emerging viral threat
8. J Autoimmun, 106 (2020), p. 102375, 10.1016/j.jaut.2019.102375
9. C.B. Planitzer, J. Modrof, T.R. KreilWest Nile virus neutralization by US plasma-derived immunoglobulin products
10. J Infect Dis, 196 (2007), pp. 435-440, 10.1086/519392
11. M. Haley, A.S. Retter, D. Fowler, J. Gea-Banacloche, N.P. O’GradyThe role for intravenous immunoglobulin in the treatment of West Nile virus encephalitis Clin Infect Dis, 37 (2003), pp. e88-e90, 10.1086/377172
12. O. Garraud, F. Heshmati, B. Pozzetto, F. Lefrere, R. Girot, A. Saillol, et al.Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow
13. Transfus Clin Biol, 23 (2016), pp. 39-44, 10.1016/j.tracli.2015.12.003
14. O. Garraud, F. Heshmati, B. Pozzetto, F. Lefrere, R. Girot, A. Saillol, et al.Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow
15. Transfus Clin Biol, 23 (2016), pp. 39-44, 10.1016/j.tracli.2015.12.003
16. J.D. Lünemann, F. Nimmerjahn, M.C. DalakasIntravenous immunoglobulin in neurology--mode of action and clinical efficacy
17. Nat Rev Neurol, 11 (2015), pp. 80-89, 10.1038/nrneurol.2014.253
18. Dis. doi:10.1093/infdis/jiaa228
19. D. McGonagle, K. Sharif, A. O’Regan, C. BridgewoodThe role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease
20. Autoimmun Rev (2020), 10.1016/j.autrev.2020.102537
21. In press:102537
22. Zeng QL, Yu ZJ, Gou JJ, et al. Effect of convalescent plasma therapy on viral shedding and survival in COVID-19 patients [published online April 29, 2020]. J Infect
23. P. Tiberghien, X. deLambalerie, P. Morel, P. Gallian, K. Lacombe, Y. YazdanpanahCollecting and evaluating convalescent plasma for COVID-19 treatment: Why and how
24. Vox Sang (2020), 10.1111/vox.12926
25. E.M. Bloch, S. Shoham, A. Casadevall, B.S. Sachais, B. Shaz, J.L. Winters, et al.Deployment of convalescent plasma for the prevention and treatment of COVID-19
26. J Clin Invest (2020), 10.1172/JCI138745
27. L. Du, Y. He, Y. Zhou, S. Liu, B.-J. Zheng, S. JiangThe spike protein of SARS-CoV--a target for vaccine and therapeutic development
28. Nat Rev Microbiol, 7 (2009), pp. 226-236, 10.1038/nrmicro2090
29. P.-R. Hsueh, L.-M. Huang, P.-J. Chen, C.-L. Kao, P.-C. YangChronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus
30. Clin Microbiol Infect, 10 (2004), pp. 1062-1066, 10.1111/j.1469-0691.2004.01009.x
31. G.J. Gorse, M.M. Donovan, G.B. PatelAntibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus-associated illnesses
32. J Med Virol, 92 (2020), pp. 512-517, 10.1002/jmv.25715
33. M. Rokni, V. Ghasemi, Z. TavakoliImmune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS
34. Rev Med Virol (2020), 10.1002/rmv.2107
35. Y. Zhang, M. Xiao, S. Zhang, P. Xia, W. Cao, W. Jiang, et al.Coagulopathy and antiphospholipid antibodies in patients with Covid-19
36. N Engl J Med, 382 (17) (2020), p. e38, 10.1056/NEJMc2007575
37. https://covid19.who.int/?gclid=Cj0KCQjw2or8BRCNARIsAC_ppyYuge-twBBhLm-h7SDeVGGp_mJic0-kXW6nIx5X-Hg1yHTC9WdrLP0aAlgJEALw_wcB
38. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200306-sitrep-46-covid-19.pdf?sfvrsn=96b04adf_4
39. Jin Young Ahn, Yujin Sohn,Su Hwan Lee, Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea
40. J Korean Med Sci, 2020 Apr 13;35(14):e149. doi.org/10.3346/jkms.2020.35.e149
41. Kai Duan, Bende Liu, Ceshend Li, Effectiveness of convalescent plasma therapy in severe Covid-19 patients. 9490-9496,PNAS April 28,2020,vol. 117, no. 17. doi.org/10.3410/f.737695760.793573172
42. Ling Li, Wei Zhang, Yu Hu, Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19
43. JAMA. 2020;324(5):460-470. doi:10.1001/jama.2020.10044
44. Anup Agarwal, Aparna Mukherjee,Gunjan Kumar; Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial)
45. medRxiv preprint doi: https://doi.org/10.1101/2020.09.03.20187252, September 10, 2020.
46. Raymond M Johnson,Joseph M Vinetz, Dexamethasone in the management of covid 19. BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m2648 (Published 03 July 2020)Cite this as: BMJ 2020;370:m2648
47. John H. Beigel, Kay M. Tomashek, Lori E. Dodd; Remdesivir for the Treatment of Covid-19 https://www.nejm.org/doi/full/10.1056/NEJMoa2007764.